This study tests whether a new tablet, S-217622, prevents COVID-19 symptoms in people who live with someone with COVID-19. COVID-19 is a disease caused by a virus called SARS-CoV-2. The virus can be detected with a special test called RT-PCR. In this study, some people will take S-217622 while others will take a placebo, which is a tablet that doesn’t have the active medicine.
There will be two groups:
- Index Participants: These people have COVID-19 symptoms and a positive SARS-CoV-2 test. They will not take the study medicine.
- Study Participants: These people do not have COVID-19 symptoms and have a negative SARS-CoV-2 test. They will take either S-217622 or a placebo.
- This study includes people aged 12 and above.
- Participants need to share living spaces, like bathrooms, with the index participant.
- Participants cannot have received a COVID-19 vaccine or certain treatments recently.
People with positive tests, certain health issues, or who are pregnant cannot join. The study will ensure that participants are safe and that the data collected is reliable.
How understandable was the trial content above?
Hard to understand
Easy to understand